Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Trial Profile

Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 22 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
    • 23 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top